Compositions and methods related to tumor cell killers and vaccines
AssigneeThe Brigham and Women's Hospital, Inc.
InventorKhalid SHAH
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions for treating cancer. Various embodiments use engineered autologous or syngeneic cancer cells that home to tumors in vivo and deliver therapeutic polypeptides. Various embodiments further promote an anti-tumor immune response that can assist in treating existing tumors and provide protection against recurrent cancer.
Claims28
A tumor cell engineered to express heterologous polypeptides including:
- (i) a receptor-mediated cell death-inducing polypeptide;
- (ii) an immunomodulatory polypeptide;
- (iii) a heterologous inducible cell suicide system;
- (iv) wherein the cell is further engineered to inactivate endogenous receptor for the receptor-mediated cell death-inducing polypeptide.
(canceled)
7-12. (canceled)
15-17. (canceled)
(canceled)
23-25. (canceled)
27-38. (canceled)
A tumor cell autologous to a cancer patient, the tumor cell engineered so as to:
- a) encode and express a heterologous ligand effective to kill cells of the patient's tumor(s) when re-introduced to the patient;
- b) be insensitive to killing by the ligand;
- and
- c) encode and express a heterologous inducible cell suicide system.
46-48. (canceled)
50-67. (canceled)
Dependencies are inferred from the claim text.